2024 News - NIH selects Dr. Kathleen Neuzil as Director of The Fogarty International Center | University of Maryland School of Medicine

March 28, 2024 | Deborah Kotz

Dr. Neuzil is the first woman to hold the permanent directorship and begins her position in May

Dr. Kathy Neuzil getting vaccinated Kathleen M. Neuzil, MD, MPH, Director of the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health, has been named the 13th director of the Fogarty International Center (FIC), which is part of the National Institutes of Health (NIH). Dr. Neuzil will be the first woman to hold the permanent directorship since the center’s founding in 1968 and will also hold the position of Associate Director for International Research at NIH.

She is currently the Myron M. Levine MD, DTPH, Endowed Professor of Vaccinology, and Chief of the Division of Geographic Medicine at UMSOM and has directed the Center for Vaccine Development and Global Health (CVD) for nearly 9 years. She is expected to leave CVD and will join NIH in May.

“Dr. Neuzil has decades of experience in global health, specifically in vaccinology. Her impressive research portfolio includes clinical and epidemiological studies into dozens of infectious diseases,” said NIH Director Monica M. Bertagnolli, M.D. “Combined with her many years as a vaccine policy advisor to the Centers for Disease Control and Prevention and the World Health Organization, and her experience establishing new partnerships and directing diverse organization teams, she is very well suited to lead FIC.”

Dr. Neuzil will lead FIC in its mission of supporting and facilitating global health research conducted by U.S.-based and international investigators, building partnerships between health research institutions across the globe, and training the next generation of scientists to address global health needs. She will oversee FIC’s annual budget of approximately $86 million, the majority of which is distributed through the Center’s grant programs.

“As much as we will miss Dr. Neuzil and her extraordinary success leading CVD, I am so excited for her to have this well-deserved opportunity at NIH, and the honor to be the first woman director of Fogarty,” said Dean Mark T. Gladwin, MD, who is the John Z. and Akiko K. Bowers Distinguished Professor and Dean of UMSOM, and Vice President for Medical Affairs at University of Maryland, Baltimore. “Under her leadership, CVD’s pathbreaking vaccine and global health research profoundly shaped the most important vaccine policies around the world, including CVD’s widely-recognized leadership in vaccine research and testing–globally and locally–during the most challenging periods of the COVID-19 pandemic.”

Dr. Neuzil’s robust research portfolio features more than 330 scientific publications on vaccines and infectious disease research. She has received NIH, other governmental and philanthropic funding throughout her career s At UMSOM’s CVD, she leads a large Gates-funded consortium (TyVAC) to accelerate the introduction of the typhoid vaccine into low resource countries and has a robust influenza research program, including a Collaborative Influenza Vaccine Innovation Center (CIVIC) Clinical Core to develop and test more broadly reactive and longer lasting influenza vaccines. Her research capabilities are complemented by 20 years of involvement in domestic and international policy. Dr. Neuzil has a strong commitment to mentoring the next generation of scientists and leaders in the field.

“It has been a privilege to lead CVD since 2015,” said Dr. Neuzil. “CVD sets the standard for academic Vaccinology, and the impact of our work, domestically and internationally, has been measured in countless lives saved. I look forward to following the future successes of CVD with pride as I transition to this exciting new opportunity.”

For over 40 years, researchers in CVD have worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. CVD is an academic enterprise engaged in the full range of infectious disease intervention from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments. CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal Salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, coronaviruses, malaria, and other infectious diseases.

Over the course of her career, Dr. Neuzil has received numerous awards. Among them, in 2022, she was named Marylander of the Year by the Baltimore Sun for her unprecedented leadership on COVID vaccines and treatment research. In 2016, she received the Vanderbilt University School of Medicine Distinguished Alumna Award, and in 2014 she was named by Vaccine Nation as “One of 50 Most Influential Persons in Vaccines.” In 2022, she was profiled in a book published by the American Association for Physician Leadership (AAPL): Lessons Learned: Stories from Women Physician Leaders. She was elected to the prestigious National Academy of Medicine in 2019.

Dr. Neuzil received her undergraduate degree in zoology from the University of Maryland, College Park. She earned her M.D. from Johns Hopkins University School of Medicine, Baltimore, and completed her internship and residency at Vanderbilt University School of Medicine, Nashville, Tennessee. While at Vanderbilt, she also completed a fellowship in infectious diseases and earned her master’s in public health. She is a member of the World Health Organization Strategic Advisory Group of Experts on Immunization. She also previously served on CDC’s Advisory Committee on Immunization Practices.

Read the Injecting Hope CVD E-Newsletter >

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic, and clinically based care for nearly 2 million patients each year. The School of Medicine has more than $500 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2023, the UM School of Medicine is ranked #10 among the 92 public medical schools in the U.S., and in the top 16 percent (#32) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

About the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine

For over 40 years, researchers in the Center for Vaccine Development and Global Health (CVD) have worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. CVD is an academic enterprise engaged in the full range of infectious disease intervention from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments. CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal Salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, coronaviruses, malaria, and other infectious diseases. CVD’s research covers the broader goal of improving global health by conducting innovative, leading research in Baltimore and around the world. Our researchers are developing new and improved ways to diagnose, prevent, treat, control, and eliminate diseases of global impact, including COVID-19. In addition, CVD’s work focuses on the ever-growing challenge of antimicrobial resistance.

Contact

Deborah Kotz
Senior Director of Media Relations
Office of Public Affairs & Communications
University of Maryland School of Medicine
DKotz@som.umaryland.edu
o: 410-706-4255
c: 617-898-7955
t: @debkotz2

Kirsten E. Lyke, MD, Professor of Medicine and Physician-Scientist at the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), was elected this week as a new member of the National Academy of Medicine (NAM). She was recognized for her pivotal research in emerging infections and human challenge models that have informed and shaped global vaccine and public health policy.

Thursday, January 26, 2023

Small Study Shows Promise for Antimalarial Monoclonal Antibody to Prevent Malaria

A monoclonal antibody treatment was found to be safe, well tolerated, and effective in protecting against malaria in a small group of healthy volunteers who were exposed to malaria in a challenge study, according to new research published in by researchers at the University of Maryland School of Medicine (UMSOM).

Tuesday, December 20, 2022

COVID Vaccines Prevented 3 Million Deaths in the U.S., New Analysis Finds

In the two years since the first COVID-19 vaccines were given to patients in the U.S., the vaccines had the cumulative effect of preventing 18 million hospitalizations and 3 million deaths. That is based on a new modeling analysis conducted by a researcher at the University of Maryland School of Medicine (UMSOM) and her colleagues. Results of the analysis were published by the Commonwealth Fund.

Tuesday, August 09, 2022

New Study Confirms Typhoid Vaccine Safety, Immune Response in Children

A new study, published in The Lancet Global Health, finds typhoid conjugate vaccine, Typbar TCV®, provides immunity for up to 3 years in children as young as 9 months old in Malawi. The research – conducted by the Blantyre Malaria Project, Malawi-Liverpool-Wellcome Trust, and researchers at the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) – found that the TCV vaccine is safe and well tolerated. Importantly, the vaccine can be given to 9-month-old infants at the same time as routine measles-rubella vaccinations without reducing the immune response to either vaccine.

Monday, August 08, 2022

New Study Finds Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against Omicron Subvariant BA.5

A study led in part by investigators at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health found that although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, those antibody levels decrease substantially within three months. Kirsten E. Lyke, MD, Professor of Medicine at UMSOM and scientist at CVD, is Co-Chair and site Principal Investigator for the study, and Meagan Deming, MD, PhD, Assistant Professor of Medicine at the UMSOM, also a scientist at CVD, is Vice-Chair of the study, which is a collaboration between investigators at the UMSOM’s CVD and the Institute of Human Virology (IHV).

Thursday, March 24, 2022

UM School of Medicine Leads Research to Assess Meningococcal Vaccine for Infants and Young Children in Africa

Researchers at the University of Maryland School of Medicine (UMSOM)’s Center for Vaccine Development & Global Health (CVD) are leading a study to evaluate the use of a pentavalent – or five in one – meningococcal conjugate vaccine (NmCV-5) among infants and young children in the meningitis belt of sub-Saharan Africa. This is the final and pivotal study for World Health Organization (WHO) prequalification of this vaccine, which is the last stage to make the vaccine available for low- and middle-income countries.

Thursday, September 16, 2021

First Efficacy Results from Africa find Typhoid Vaccine to offer 84 Percent Protection against Typhoid Fever

A new study, published in the New England Journal of Medicine, finds a single dose of typhoid conjugate vaccine (TCV) – the only typhoid vaccine licensed for children as young as 6 months – is safe and 84 percent effective in protecting against typhoid in Blantyre, Malawi. These are the first efficacy results from Africa and part of a five-year, multi-country project to accelerate introduction of TCV.

Friday, February 05, 2021

UM School of Medicine Researchers Demonstrate Strong Immune Response for New COVID-19 Vaccine in Pre-Clinical Tests

Researchers at the University of Maryland School of Medicine (UMSOM) have found promising results in pre-clinical studies for a new experimental vaccine against COVID-19 made by Novavax. The vaccine was found to generate a robust immune response in animals exposed to the vaccine with strong data indicating safety and efficacy, according to the study published recently in the journal Nature Communications. The results have been used to begin testing the vaccine in human trials in the U.S. with a Phase 3 trial that recently launched at the UMSOM’s Center for Vaccine Development and Global Health.

Tuesday, January 05, 2021

Dr. Kathleen Neuzil, World-renowned Leader in Vaccine Research, Receives Moderna Vaccine

Kathleen Neuzil, MD, MPH, FIDSA, the Myron M. Levine, MD, DTPH, Professor of Vaccinology and Director of the University of Maryland School of Medicine’s (UMSOM)’s Center for Vaccine Development and Global Health (CVD), received her first injection of the Moderna vaccine for COVID-19 on December 31. Researchers at the University of Maryland School of Medicine (UMSOM) played an integral part in the dedicated work that led to the U.S. Food and Drug Administration issuing an Emergency Use Authorization for the Moderna vaccine in December.

Tuesday, December 10, 2019

UMSOM Researchers to Test Vaccine Designed to Protect Against Serious Illness from Contaminated Food and Water

Each year, millions of people contract serious diarrheal illnesses typically from contaminated food and water. Among the biggest causes of diarrheal diseases are the bacteria Shigella and enterotoxigenic Escherichia coli (ETEC), and researchers at the University of Maryland School of Medicine are testing a vaccine designed to offer protection against these serious pathogens.

Friday, September 20, 2019

UM School of Medicine's Center for Vaccine Development and Global Health Receives NIH Contract of up to More than $200 Million for Influenza Research

Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with total funding up to more than $200 million over seven years if all contract options are exercised.

Monday, August 19, 2019

UM School of Medicine Researcher Warns of Need for Malaria Drug to Treat Severe Cases in U.S.

Each year there are more than 200 million cases of malaria worldwide, a mosquito-borne disease caused by a parasite that brings on fever and body aches and, in some cases, more serious conditions such as coma and death. While the vast majority of these cases occur in sub-Saharan Africa and South Asia, the U.S. each year sees more than 1,500 cases, and currently there is limited access to an intravenously-administered (IV) drug needed for the more serious cases, according to a top malaria researcher at the University of Maryland School Medicine (UMSOM).

Tuesday, August 13, 2019

UM School of Medicine Researchers Begin Phase 1 Clinical Trial of Vaccine Against Mosquito-Borne Diseases

Mosquito-borne diseases including malaria, dengue and yellow fever, have a severe impact resulting in millions of deaths worldwide, hitting the world’s most vulnerable populations the hardest. Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental vaccine that is designed to protect against a series of these diseases.

Friday, November 02, 2018

UMSOM Global Health Expert Named to Prestigious World Health Organization Immunization Panel

Wednesday, June 06, 2018

UMSOM Researchers Find that Silent Carriers of Malaria are Unlikely to Develop the Disease

In regions where malaria illness is widespread, it is common to find many individuals who are infected with malaria parasites (Plasmodium falciparum), but without symptoms. New research conducted by the University of Maryland School of Medicine (UMSOM) shows that treating these silent malaria cases could help stop the spread of malaria to others.

Tuesday, May 15, 2018

Tackling Malaria Transmission in Sub-Saharan Africa

Two malaria experts in the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine wrote a commentary published in the June Issue of The Lancet Global Health discussing the prevalence of malaria in school-age children in sub-Saharan Africa. Miriam Laufer, MD, Associate Professor of Pediatrics and Associate Director for Malaria Research CVD, and Lauren Cohee, MD, Instructor, Pediatrics, noted that often malaria infection is more common in school-age children than younger children and adults.

Tuesday, March 20, 2018

UMSOM Vaccine Experts Lead Trial on Avian Flu Vaccine

Vaccine experts at the University of Maryland School of Medicine (UMSOM) have begun multiple clinical trials of vaccines designed to protect against H7N9, an avian influenza virus that was first reported in humans in 2013 in China.

Friday, December 23, 2016

Trial Results Confirm Ebola Vaccine Provides High Protection Against Disease

An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to a new study that included researchers from the University of Maryland School of Medicine (UM SOM).

Monday, January 11, 2016

UM SOM to Collaborate with Industry to Develop a Vaccine to Prevent Common, Deadly Infection

The Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM) will participate in a partnership with industry to develop a vaccine to prevent a group of deadly bacterial infections that occur commonly among hospital patients

NIH selects Dr. Kathleen Neuzil as Director of The Fogarty International Center